AKTX News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AK

Mkt Cap

$18.7M

Volume

21.62K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC InnovationAkari Therapeutics announced a strategic research collaboration with WhiteHawk Therapeutics to combine Akari's PH1 spliceosome-modulating payload with WhiteHawk's TOP1 inhibitor ADC platform for a novel dual-payload strategy. The company is advancing its lead candidate AKTX-101 toward Phase 1 clinical evaluation by mid-2027 and emphasizes that collaborations will play an increasingly important role in advancing next-generation ADC innovation.GlobeNewswire Inc. · Aug 4, 2026

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026Akari Therapeutics announced progress in 2025 and outlined its path toward clinical transition in 2026. The company established a manufacturing partnership with WuXi Biologics and initiated pre-filing activities, with plans to launch its First-in-Human clinical trial by late 2026/early 2027. The company's lead candidate AKTX-101 is an ADC targeting Trop2 with a novel PH1 spliceosome-modulating payload designed to deliver dual mechanisms of action: direct tumor cytotoxicity and immune activation.GlobeNewswire Inc. · Jan 9, 2026

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak BioAkari Therapeutics has successfully completed the merger with Peak Bio, creating an innovative biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The combined entity secured $3.2 million in PIPE financing and a $50 million term sheet for an equity line of credit to support its pipeline development.Benzinga · Nov 14, 2024

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent HighlightsEntered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024GlobeNewswire Inc. · May 16, 2024

Samir R. Patel, M.D. Appointed Interim CEO for Akari TherapeuticsBOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. as interim CEO.GlobeNewswire Inc. · May 1, 2024

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent HighlightsBOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights.GlobeNewswire Inc. · Apr 1, 2024

Akari Therapeutics to Present at Biotech Showcase 2024NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that President and CEO Rachelle Jacques will present a company overview for in-person and virtual attendees at Biotech Showcase taking place in San Francisco, CA January 8-10, 2024, adjacent to the J.P. Morgan Healthcare Conference 2024. Akari management will attend one-on-one meetings during the conferences.GlobeNewswire Inc. · Dec 14, 2023

Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of DirectorsNEW YORK and BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. to the Akari Board of Directors.GlobeNewswire Inc. · Dec 1, 2023

Akari Therapeutics Reports First Half 2023 Financial Results and HighlightsBOSTON and LONDON, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases today announced financial results and highlights for the first half of 2023, ended June 30th. Akari’s lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 and leukotriene B4 (LTB4). Nomacopan is in Phase 3 development for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) and is entering Phase 3 development in adult HSCT-TMA. Long-acting PAS-nomacopan is in final pre-clinical development and is advancing toward clinical trials in geographic atrophy (GA).GlobeNewswire Inc. · Sep 29, 2023

Akari Therapeutics to Present at Emerging Growth ConferenceBOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Emerging Growth Conference being held October 4 and 5, 2023. President and CEO Rachelle Jacques will present an overview of the company and its lead asset nomacopan, a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), on October 4, 2023 from 11:25 am to 11:55 am ET.GlobeNewswire Inc. · Sep 27, 2023

AK

AKTXAkari Therapeutics plc ADR (0.01 USD)

AKTX

Pay with—

Available Balance0.00

Your PositionYou don't own any AKTX yet.

Related Tickers

Earnings